TD Asset Management Inc Has $75.92 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO

TD Asset Management Inc lowered its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 5.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,035,170 shares of the biopharmaceutical company’s stock after selling 55,590 shares during the quarter. TD Asset Management Inc owned approximately 0.88% of Halozyme Therapeutics worth $75,919,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC grew its stake in Halozyme Therapeutics by 13.6% during the third quarter. EverSource Wealth Advisors LLC now owns 3,049 shares of the biopharmaceutical company’s stock worth $224,000 after buying an additional 364 shares during the last quarter. Clearstead Advisors LLC raised its stake in shares of Halozyme Therapeutics by 107.7% in the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 265 shares during the last quarter. Advisors Preferred LLC acquired a new position in shares of Halozyme Therapeutics in the 3rd quarter worth approximately $1,526,000. Intrust Bank NA grew its position in Halozyme Therapeutics by 42.5% during the 3rd quarter. Intrust Bank NA now owns 6,565 shares of the biopharmaceutical company’s stock worth $481,000 after acquiring an additional 1,959 shares during the last quarter. Finally, Stevens Capital Management LP increased its holdings in Halozyme Therapeutics by 17.5% during the 3rd quarter. Stevens Capital Management LP now owns 5,309 shares of the biopharmaceutical company’s stock valued at $389,000 after purchasing an additional 792 shares in the last quarter. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Trading Down 1.6%

HALO stock opened at $69.22 on Friday. The company has a quick ratio of 3.66, a current ratio of 4.66 and a debt-to-equity ratio of 43.89. Halozyme Therapeutics, Inc. has a twelve month low of $47.50 and a twelve month high of $82.22. The company has a market cap of $8.17 billion, a P/E ratio of 27.80, a PEG ratio of 0.28 and a beta of 0.97. The business has a fifty day moving average of $72.58 and a 200-day moving average of $70.59.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of $1.92 by ($2.16). The firm had revenue of $451.77 million during the quarter, compared to the consensus estimate of $446.13 million. Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. Halozyme Therapeutics’s revenue was up 51.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.26 EPS. As a group, equities research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insider Activity at Halozyme Therapeutics

In other news, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $78.64, for a total transaction of $786,400.00. Following the completion of the sale, the chief executive officer owned 708,719 shares in the company, valued at $55,733,662.16. The trade was a 1.39% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Bernadette Connaughton sold 2,000 shares of the stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $70.25, for a total transaction of $140,500.00. Following the completion of the transaction, the director owned 40,123 shares in the company, valued at $2,818,640.75. This represents a 4.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 49,398 shares of company stock valued at $3,650,592. 2.40% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

HALO has been the subject of several research analyst reports. Wall Street Zen downgraded Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Saturday, February 21st. Benchmark raised their target price on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Wells Fargo & Company upped their price target on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 19th. Weiss Ratings lowered shares of Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a report on Tuesday. Finally, HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, January 29th. Six investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $78.56.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.